SMT201500028B - N-(4-((3-(2-ammino-4-pirimidinil)-2-piridinil)ossi)fenil)-4-(4-metil-2-tienil)-trattamento di un cancro resistente ad agenti antimitotici - Google Patents

N-(4-((3-(2-ammino-4-pirimidinil)-2-piridinil)ossi)fenil)-4-(4-metil-2-tienil)-trattamento di un cancro resistente ad agenti antimitotici

Info

Publication number
SMT201500028B
SMT201500028B SM201500028T SM201500028T SMT201500028B SM T201500028 B SMT201500028 B SM T201500028B SM 201500028 T SM201500028 T SM 201500028T SM 201500028 T SM201500028 T SM 201500028T SM T201500028 B SMT201500028 B SM T201500028B
Authority
SM
San Marino
Prior art keywords
pyridinyl
pyrimidinyl
thienyl
oxy
phenyl
Prior art date
Application number
SM201500028T
Other languages
English (en)
Italian (it)
Inventor
Marc Payton
Richard Kendall
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201500028(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SMT201500028B publication Critical patent/SMT201500028B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM201500028T 2009-09-11 2015-02-09 N-(4-((3-(2-ammino-4-pirimidinil)-2-piridinil)ossi)fenil)-4-(4-metil-2-tienil)-trattamento di un cancro resistente ad agenti antimitotici SMT201500028B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24152709P 2009-09-11 2009-09-11
PCT/US2010/048247 WO2011031842A1 (en) 2009-09-11 2010-09-09 N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Publications (1)

Publication Number Publication Date
SMT201500028B true SMT201500028B (it) 2015-03-05

Family

ID=43216900

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500028T SMT201500028B (it) 2009-09-11 2015-02-09 N-(4-((3-(2-ammino-4-pirimidinil)-2-piridinil)ossi)fenil)-4-(4-metil-2-tienil)-trattamento di un cancro resistente ad agenti antimitotici

Country Status (34)

Country Link
US (1) US20120028917A1 (https=)
EP (2) EP2818170B1 (https=)
JP (1) JP5851403B2 (https=)
KR (1) KR20120082896A (https=)
CN (1) CN102869361A (https=)
AU (1) AU2010292225C1 (https=)
BR (1) BR112012008325A2 (https=)
CA (1) CA2773838C (https=)
CL (1) CL2012000640A1 (https=)
CR (1) CR20120171A (https=)
DK (1) DK2475368T3 (https=)
EA (1) EA020526B1 (https=)
ES (1) ES2528485T3 (https=)
HK (1) HK1205457A1 (https=)
HR (1) HRP20150104T1 (https=)
HU (1) HUE024568T2 (https=)
IL (1) IL218569A0 (https=)
MA (1) MA33658B1 (https=)
ME (1) ME02048B (https=)
MX (1) MX2012003041A (https=)
NZ (1) NZ598758A (https=)
PE (1) PE20120895A1 (https=)
PH (1) PH12012500504A1 (https=)
PL (1) PL2475368T3 (https=)
PT (1) PT2475368E (https=)
RS (1) RS53807B1 (https=)
SG (1) SG179102A1 (https=)
SI (1) SI2475368T1 (https=)
SM (1) SMT201500028B (https=)
TN (1) TN2012000110A1 (https=)
TW (1) TW201121956A (https=)
UA (1) UA107675C2 (https=)
WO (1) WO2011031842A1 (https=)
ZA (1) ZA201202472B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921367B2 (en) 2012-05-31 2014-12-30 Amgen Inc. Use of AMG 900 for the treatment of cancer
CN103664737A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
KR101701235B1 (ko) 2013-09-30 2017-02-03 한국원자력의학원 Hrp-3 억제제를 포함하는 방사선 또는 약물내성 암의 치료용 약학 조성물
BR112016010564A2 (pt) 2013-11-11 2017-10-10 Amgen Inc terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres
WO2015084649A1 (en) 2013-12-03 2015-06-11 Amgen Inc. Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
RU2713179C2 (ru) * 2014-02-21 2020-02-04 Фрост Биолоджик, Инк. Антимитотические амиды для лечения рака и пролиферативных заболеваний
EP3443351A4 (en) * 2016-04-15 2019-12-18 Felicitex Therapeutics, Inc. COMBINATIONS FOR THE TREATMENT OF NEOPLASIA BY TARGETING RESTING CELLS AND INHIBITORS OF MITOSIS
AU2018273356B2 (en) 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
AU2018329920B2 (en) 2017-09-08 2022-12-01 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
CA3098574A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2020236947A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178318A1 (en) * 2003-07-03 2006-08-10 Shubha Anand Use of aurora kinase inhibitors for reducing the resistance of cancer cells
CN101405282B (zh) * 2006-01-23 2015-03-25 安姆根有限公司 极光激酶调节剂和使用方法
DK1984353T3 (en) * 2006-01-23 2016-03-14 Amgen Inc Aurorakinasemodulatorer and method of use
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal

Also Published As

Publication number Publication date
JP2013504582A (ja) 2013-02-07
US20120028917A1 (en) 2012-02-02
CR20120171A (es) 2012-08-09
JP5851403B2 (ja) 2016-02-03
RS53807B1 (sr) 2015-06-30
MA33658B1 (fr) 2012-10-01
MX2012003041A (es) 2012-06-27
SI2475368T1 (sl) 2015-03-31
CL2012000640A1 (es) 2012-09-21
ES2528485T3 (es) 2015-02-10
TN2012000110A1 (en) 2013-09-19
HK1173655A1 (en) 2013-05-24
UA107675C2 (xx) 2015-02-10
EP2475368B1 (en) 2014-12-17
DK2475368T3 (en) 2015-03-09
EP2475368A1 (en) 2012-07-18
AU2010292225C1 (en) 2013-06-27
HRP20150104T1 (xx) 2015-03-13
PH12012500504A1 (en) 2015-04-29
ME02048B (me) 2015-05-20
TW201121956A (en) 2011-07-01
NZ598758A (en) 2013-12-20
CN102869361A (zh) 2013-01-09
WO2011031842A1 (en) 2011-03-17
HK1205457A1 (en) 2015-12-18
CA2773838A1 (en) 2011-03-17
EP2818170B1 (en) 2018-12-05
IL218569A0 (en) 2012-05-31
BR112012008325A2 (pt) 2017-08-29
CA2773838C (en) 2016-05-31
ZA201202472B (en) 2012-12-27
EA201270383A1 (ru) 2013-04-30
EA020526B1 (ru) 2014-11-28
AU2010292225B2 (en) 2012-12-13
SG179102A1 (en) 2012-04-27
HUE024568T2 (hu) 2016-02-29
KR20120082896A (ko) 2012-07-24
PE20120895A1 (es) 2012-08-19
EP2818170A1 (en) 2014-12-31
AU2010292225A1 (en) 2012-04-12
PT2475368E (pt) 2015-02-10
PL2475368T3 (pl) 2015-05-29

Similar Documents

Publication Publication Date Title
SMT201500028B (it) N-(4-((3-(2-ammino-4-pirimidinil)-2-piridinil)ossi)fenil)-4-(4-metil-2-tienil)-trattamento di un cancro resistente ad agenti antimitotici
SMT201600304B (it) Sale cloridrato di 4-[2-[[5-metil-1-(2- naftalenil]-1h-pirazol-3- il]ossi]etil]morfolina
FR18C1020I2 (fr) Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide
DK2191831T3 (da) Modificering af pirfenidon-behandling for patienter med atypisk leverfunktion
DK2318396T3 (da) Krystalform af posaconazol
DK2064189T3 (da) Polymorfe former af 4-[3-(4-cyklopropancarbonyl-piperazin-1-carbonyl)-4-fluor-benzyl]-2H-phathalazin-1-on
DK2398785T3 (da) Oprensning af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazin
BRPI0817537A2 (pt) 4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona
DK2086642T3 (da) Dnase til behandling af subfertilitet hos mænd
PL2503993T3 (pl) Chlorowodorek 4-[2-[[5-metylo-1-(2-naftalenylo)-1H-pirazol-3-ilo]oksy]etylo]morfoliny
BRPI0921596A2 (pt) Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina
EP2446315A4 (en) MODULAR MICROSCOPE CONSTRUCTION
SMT201600031B (it) Composti eterociclici di fenossimetile
EP2735414A4 (en) CUT PROCESSING MECHANISM
DK2175849T3 (da) Behandling af melanomer
PL2722046T3 (pl) Postać krystaliczna 1 2-((R)-2-metylopirolidyn-2-ylo)-1H-benzoimidazolo-4-karboksyamidu
ATE514685T1 (de) Herbizid wirksame 4- (3-aminobenzoyl) -5- cyclopropylisoxazole
IL200959A0 (en) Liquid formulations of salts of 4-[2-(4-methylphenylfanyl)phenyl]piperidine
EP2427452A4 (en) P38 KINASE-INHIBITABLE ACTIVE SUBSTANCES
IT1395453B1 (it) Assieme placca/controplacca di comando di una cassetta di risciacquo
DK2516418T3 (da) Pro-drugs af [4[4-(5-aminomethyl-2-fluor-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanoner og syntese deraf
HK1176863A (en) Hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine
UA17116S (uk) Набір офісних меблів
UA17976S (uk) Комплект одягу для офіціанта
UA17977S (uk) Комплект одягу для офіціанта